Graham Lumsden, Chief Executive Officer

Graham G. Lumsden, Chief Executive Officer of Motif, is responsible for all aspects of the strategy, management, and operations of the Company. Prior to joining Motif, Mr. Lumsden was a senior executive at Merck & Co., Inc. where he held commercial leadership positions in worldwide businesses including contraceptives and osteoporosis. Mr. Lumsden has a proven record of success leading change and delivering results in subsidiary and global leadership positions, including new product launches, pre-clinical/clinical development, regulatory strategy, cross-functional team leadership, IP strategy/litigation, and domestic/international sales and marketing. Mr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS), holds a postgraduate diploma from the Chartered Institute of Marketing (MCIM), and is a dual citizen of the U.S. and UK.

Robert Dickey, IV, Chief Financial Officer

Robert Dickey IV, Chief Financial Officer, has broad senior leadership experience at public and private life sciences companies. Prior to Motif, he was CFO at Tyme Technologies, a publicly-traded oncology company. Prior to Tyme, he was CFO at NeoStem, Inc. (now Caladrius Biosciences), a public, regenerative medicines company. He previously served as SVP at Hemispherx Biopharma, SVP, CFO and Business Unit Manager at StemCyte, Inc., CFO at Locus Pharmaceuticals and COO and CEO at Protarga, Inc. Before that, he spent 18 years as an investment banker, mostly at Lehman Brothers, with a background split between M&A and capital markets transactions. Mr. Dickey holds an MBA from The Wharton School, University of Pennsylvania, and an AB from Princeton University.

David Huang, M.D., Ph.D, Chief Medical Officer

Dr. Huang is a senior pharmaceutical research executive, and the former Chief Medical Officer at ContraFect Corporation where he had the responsibility for the development of biologic anti-infectives, including bacteriophage lysins and monoclonal antibodies. Dr. Huang has also led drug development groups in anti-infectives at Pfizer and Boehringer-Ingelheim. Dr. Huang has 15 years of clinical, academic and research experience in medicine and in the subspeciality of infectious diseases. He has served as a faculty member at Baylor College of Medicine and currently as an adjunct Assistant Professor at Rutgers New Jersey Medical School. His research interests include bacteriology and virology, especially the epidemiology, pathogenesis, and treatment of multi-drug resistant organisms. He is well versed in the design, execution and close out of Phase I – III clinical trials for both antibacterials and antiviral agents. Dr. Huang completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas at Southwestern and fellowship in infectious diseases at Baylor College of Medicine.

Rajesh B. Shukla, Ph.D., Vice President, Clinical Operations

Dr. Shukla brings drug discovery, clinical development, and clinical operations experience from entrepreneurial and established pharmaceutical companies as well as with HHS and DoD/MoD agencies. Prior to joining Motif, Dr. Shukla headed early through NDA stage clinical development programs in Infectious Diseases, Epilepsy, Oncology, Endocrinology, Asthma, and Anaphylaxis clinical programs at Pfizer, Bristol-Myers Squibb, Bracco Diagnostics, Teva and, most recently, Acorda Therapeutics. He began his pharmaceutical career at Bristol Myers-Squibb with a discovery focus in Oncology, CNS, and late clinical stage experience in Anti-infectives programs. Dr. Shukla completed his bachelor’s degree in Biochemistry from Lehigh University and his Ph.D. from Carnegie-Mellon University followed by a postdoctoral fellowship at Yale University.